Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions
Plasmablastic lymphoma (PBL) is an aggressive subtype of non-Hodgkin’s lymphoma (NHL), which frequently arises in the oral cavity of human immunodeficiency virus (HIV) infected patients. PBL shows diffuse proliferation of large neoplastic cells resembling B-immunoblasts/plasmablasts, or with plasmac...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2015/315289 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563133833543680 |
|---|---|
| author | Ghaleb Elyamany Eman Al Mussaed Ali Matar Alzahrani |
| author_facet | Ghaleb Elyamany Eman Al Mussaed Ali Matar Alzahrani |
| author_sort | Ghaleb Elyamany |
| collection | DOAJ |
| description | Plasmablastic lymphoma (PBL) is an aggressive subtype of non-Hodgkin’s lymphoma (NHL), which frequently arises in the oral cavity of human immunodeficiency virus (HIV) infected patients. PBL shows diffuse proliferation of large neoplastic cells resembling B-immunoblasts/plasmablasts, or with plasmacytic features and an immunophenotype of plasma cells. PBL remains a diagnostic challenge due to its peculiar morphology and an immunohistochemical profile similar to plasma cell myeloma (PCM). PBL is also a therapeutic challenge with a clinical course characterized by a high rate of relapse and death. There is no standard chemotherapy protocol for treatment of PBL. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens have been the backbone while more intensive regimens such as cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, high-dose cytarabine (CODOX-M/IVAC), or dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) are possible options. Recently, a few studies have reported the potential value of the proteasome inhibitor bortezomib and thalidomide in PBL patients. The introduction of genes encoding artificial receptors called chimeric antigen receptors (CARs) and CAR-modified T cells targeted to the B cell-specific CD19 antigen have demonstrated promising results in multiple early clinical trials. The aim of this paper is to review the recent advances in epidemiology; pathophysiology; clinical, pathologic, and molecular characteristics; therapy; and outcome in patients with PBL. |
| format | Article |
| id | doaj-art-22b0ae5a5d6346109bc3131da9b9c558 |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-22b0ae5a5d6346109bc3131da9b9c5582025-02-03T01:20:47ZengWileyAdvances in Hematology1687-91041687-91122015-01-01201510.1155/2015/315289315289Plasmablastic Lymphoma: A Review of Current Knowledge and Future DirectionsGhaleb Elyamany0Eman Al Mussaed1Ali Matar Alzahrani2Department of Pathology and Blood Bank, Prince Sultan Military Medical City, P.O. Box 7897, Riyadh 11159, Saudi ArabiaHematopathology Division, Department of Basic Science, College of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi ArabiaDepartment of Oncology, Prince Sultan Military Medical City, Saudi ArabiaPlasmablastic lymphoma (PBL) is an aggressive subtype of non-Hodgkin’s lymphoma (NHL), which frequently arises in the oral cavity of human immunodeficiency virus (HIV) infected patients. PBL shows diffuse proliferation of large neoplastic cells resembling B-immunoblasts/plasmablasts, or with plasmacytic features and an immunophenotype of plasma cells. PBL remains a diagnostic challenge due to its peculiar morphology and an immunohistochemical profile similar to plasma cell myeloma (PCM). PBL is also a therapeutic challenge with a clinical course characterized by a high rate of relapse and death. There is no standard chemotherapy protocol for treatment of PBL. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens have been the backbone while more intensive regimens such as cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, high-dose cytarabine (CODOX-M/IVAC), or dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) are possible options. Recently, a few studies have reported the potential value of the proteasome inhibitor bortezomib and thalidomide in PBL patients. The introduction of genes encoding artificial receptors called chimeric antigen receptors (CARs) and CAR-modified T cells targeted to the B cell-specific CD19 antigen have demonstrated promising results in multiple early clinical trials. The aim of this paper is to review the recent advances in epidemiology; pathophysiology; clinical, pathologic, and molecular characteristics; therapy; and outcome in patients with PBL.http://dx.doi.org/10.1155/2015/315289 |
| spellingShingle | Ghaleb Elyamany Eman Al Mussaed Ali Matar Alzahrani Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions Advances in Hematology |
| title | Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions |
| title_full | Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions |
| title_fullStr | Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions |
| title_full_unstemmed | Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions |
| title_short | Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions |
| title_sort | plasmablastic lymphoma a review of current knowledge and future directions |
| url | http://dx.doi.org/10.1155/2015/315289 |
| work_keys_str_mv | AT ghalebelyamany plasmablasticlymphomaareviewofcurrentknowledgeandfuturedirections AT emanalmussaed plasmablasticlymphomaareviewofcurrentknowledgeandfuturedirections AT alimataralzahrani plasmablasticlymphomaareviewofcurrentknowledgeandfuturedirections |